Systemic Vasculitis in Children

1. Endesh Kyzy Gulsara

2. Himanshu Bairwa

    Kashish Rai

(1. Teacher, Osh State University, Osh, Kyrgyz Republic.

2. Students, Osh State University, Osh, Kyrgyz Republic.)

Introduction

Systemic vasculitis in children comprises a diverse group of disorders characterized by inflammation of blood vessel walls, leading to tissue ischemia and organ dysfunction. Pediatric vasculitis differs from adult forms in etiology, clinical presentation, and outcomes. The most common types include IgA vasculitis (Henoch–Schönlein purpura), Kawasaki disease, and less frequently, polyarteritis nodosa and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Early recognition and appropriate management are essential to prevent long-term complications such as renal impairment, coronary artery aneurysms, and chronic organ damage.

Methods

A narrative review was conducted using PubMed, Scopus, and Google Scholar databases. Articles published between 2010 and 2025 were included. Search terms used were “systemic vasculitis,” “children,” “pediatric vasculitis,” “Kawasaki disease,” “Henoch–Schönlein purpura,” and “polyarteritis nodosa.” Clinical trials, cohort studies, and review articles focusing on pediatric populations were analyzed. Data were extracted regarding epidemiology, pathogenesis, clinical features, diagnostic criteria, and management strategies. Due to heterogeneity among studies, a qualitative synthesis was performed.

Results

Epidemiology

IgA vasculitis is the most common systemic vasculitis in children, with an incidence of 10–20 per 100,000 annually. Kawasaki disease primarily affects children under five years of age, with higher prevalence in East Asian populations. Polyarteritis nodosa and ANCA-associated vasculitis are rare but associated with significant morbidity and mortality.

Pathogenesis

The pathogenesis involves immune complex deposition, autoantibody formation, and cytokine-mediated endothelial injury. Genetic predisposition and environmental triggers, including infections, contribute to disease onset. IgA vasculitis often follows upper respiratory infections, while Kawasaki disease may be triggered by viral or bacterial superantigens. Dysregulated immune responses lead to vascular inflammation and tissue damage.

Clinical Features

Clinical manifestations depend on the size and distribution of affected vessels. IgA vasculitis presents with palpable purpura, arthralgia, abdominal pain, and renal involvement. Kawasaki disease is characterized by prolonged fever, mucocutaneous inflammation, lymphadenopathy, and risk of coronary artery aneurysms. Polyarteritis nodosa may present with systemic symptoms, hypertension, and organ ischemia. ANCA-associated vasculitis can involve the kidneys, lungs, and upper respiratory tract.

Diagnosis

Diagnosis is based on clinical criteria supported by laboratory and imaging findings. Elevated inflammatory markers (ESR, CRP), abnormal urinalysis, and specific serologic tests (e.g., ANCA) aid in diagnosis. Imaging modalities such as echocardiography and angiography are essential for assessing vascular involvement. Biopsy may confirm vasculitic changes in affected tissues.

Management

Treatment depends on disease type and severity. Corticosteroids remain the cornerstone of therapy for most forms. Immunosuppressive agents such as cyclophosphamide, azathioprine, or methotrexate are used in severe or refractory cases. Intravenous immunoglobulin (IVIG) is the mainstay of Kawasaki disease management, significantly reducing the risk of coronary complications. Supportive care, including blood pressure control and renal monitoring, is essential. Long-term follow-up is required to detect relapses and manage chronic sequelae.

Discussion

Systemic vasculitis in children presents diagnostic and therapeutic challenges due to its variable clinical spectrum and potential for multisystem involvement. Advances in immunopathology have improved understanding of disease mechanisms, leading to more targeted therapies. Early diagnosis and prompt initiation of treatment are critical to improving outcomes. Despite progress, long-term complications such as renal impairment and cardiovascular sequelae remain concerns. Future research should focus on identifying biomarkers for early detection, refining classification criteria, and developing safer, more effective therapies tailored to pediatric populations.

Conclusion

Pediatric systemic vasculitis encompasses a spectrum of immune-mediated disorders with diverse clinical manifestations. Timely recognition, accurate diagnosis, and appropriate immunomodulatory therapy are essential to prevent irreversible organ damage. Continued research and multidisciplinary management are vital to improving prognosis and quality of life for affected children.

References

1.     Ozen S, Pistorio A, Iusan SM, et al. EULAR/PRINTO/PRES criteria for Henoch–Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis, and childhood Takayasu arteritis: Ankara 2008. Ann Rheum Dis. 2010;69(5):798–806.

2.     Eleftheriou D, Brogan PA. Vasculitis in children. Best Pract Res Clin Rheumatol. 2020;34(2):101–115.

3.     McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: A scientific statement for health professionals. Circulation. 2017;135(17):e927–e999.

4.     Jennette JC, Falk RJ, Bacon PA, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1–11.

5.     Batu ED, Ozen S. Pediatric vasculitis: General concepts. Front Pediatr. 2018;6:265.

6.     Heaton JM, Davies K, Eleftheriou D, Brogan PA. Systemic vasculitis in children: A review of classification, diagnosis, and management. Front Pediatr. 2022;10:879654.

7.     Weiss PF. Pediatric vasculitis. Pediatr Clin North Am. 2018;65(4):775–795.

8.     Kone-Paut I, Cimaz R. Current management of pediatric vasculitis. Curr Opin Rheumatol. 2021;33(5):417–424.